Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betuvax-CoV-2 booster
- Development stage
- Preclinical
- Lead developer
- Artgen Biotech
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Betuvax-CoV-2 booster is a recombinant protein subunit vaccine candidate developed by Artgen Biotech (formerly Human Stem Cells Institute) and its subsidiary Betuvax LLC for use as a booster vaccination against COVID-19. The vaccine's active component is a recombinant RBD-SD21-SD14-Fc fusion protein that targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. This antigen is anchored to 100-180 nm spherical nanoparticles composed of betulin, a natural triterpene derived from birch bark. These nanoparticles serve as a corpuscular adjuvant, mimicking the size and morphology of the virus to enhance the immune response by facilitating antigen presentation. While the primary Betuvax-CoV-2 vaccine series has progressed to clinical trials, this specific booster formulation is currently in the preclinical stage of development as part of Artgen Biotech's pipeline.
- Brand names
- Betuvax-CoV-2Betuvax-CoV2Betuvax-CoV 2
- Other names
- Бетувакс-КоВ-2 – boosterBetuvax-CoV-2 boosterBetuvax-CoV2 boosterBetuvax-CoV 2 booster
02
Targets
ACE2 (Angiotensin-converting enzyme 2)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Betuvax-CoV-2 booster.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Betuvax-CoV-2 booster.